Search Press releases

14 Nov 2024

New BIMZELX[®] (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis

Read More
12 Nov 2024

Transparency notification BlackRock, Inc.

Read More
8 Nov 2024

Transparency notification BlackRock, Inc.

Read More
5 Nov 2024

UCB completes sale of established brands and updates 2024 financial guidance

Read More
31 Oct 2024

UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024

Read More
22 Oct 2024

UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

Read More

Stay up-to-date on the latest news and information from UCB